Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/24/2025 | $80.00 | Neutral → Buy | Sidoti |
| 12/9/2024 | $90.00 | Buy → Neutral | Sidoti |
| 6/21/2024 | $65.00 → $93.00 | Neutral → Buy | DA Davidson |
| 11/17/2022 | $71.00 | Buy | Canaccord Genuity |
| 5/10/2022 | $65.00 → $70.00 | Hold → Buy | Jefferies |
| 5/9/2022 | $63.00 | Perform → Outperform | Oppenheimer |
| 3/11/2022 | $156.00 → $142.00 | Outperform | BMO Capital |
| 11/15/2021 | $61.00 → $63.00 | Neutral | DA Davidson |
8-K - Prestige Consumer Healthcare Inc. (0001295947) (Filer)
SCHEDULE 13G/A - Prestige Consumer Healthcare Inc. (0001295947) (Subject)
10-Q - Prestige Consumer Healthcare Inc. (0001295947) (Filer)
Entered agreement to acquire a portfolio of brands with revenue of $200 million and EBITDA of $95 millionBreathe Right is an iconic and category‑leading brand with strong margins and cash flow generationAcquisition reinforces Prestige's long-term organic growth algorithmTransaction expected to close in Prestige's first half fiscal 2027 TARRYTOWN, N.Y., March 20, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (the "Company" or "Prestige") (NYSE:PBH) today announced that it has entered into a definitive agreement to acquire the Breathe Right® brand and certain other brands from Foundation Consumer Healthcare for $1.045 billion, or approximately $900 million net of anticipated ta
Revenue of $283.4 million in Q3, ahead of outlookDiluted EPS of $0.97 in Q3 and Adjusted Diluted EPS of $1.14, versus prior year Q3 Diluted EPS of $1.22Repurchased approximately 0.8 million shares opportunistically in Q3Successfully closed acquisition of eye care supplier Pillar5 Pharma, Inc. in December, as expectedNarrowing Outlook Range of Fiscal 2026 Revenue and Adjusted Diluted EPS TARRYTOWN, N.Y., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its third quarter and nine months ended December 31, 2025. "We exceeded our third quarter revenue outlook and delivered solid profitability in the quarter, which
TARRYTOWN, N.Y., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (the "Company" or "Prestige") (NYSE:PBH) today announced it will issue its fiscal 2026 third quarter earnings release on Thursday, February 5, 2026 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET. To participate in the live Internet webcast of the conference call, it can be accessed from the Investor Relations page of www.prestigeconsumerhealthcare.com. To participate in the conference call via phone, participants may register for the call here to receive dial-in details and a unique pin. While not required, it is recomme
Sidoti upgraded Prestige Consumer from Neutral to Buy and set a new price target of $80.00
Sidoti downgraded Prestige Consumer from Buy to Neutral and set a new price target of $90.00
DA Davidson upgraded Prestige Consumer from Neutral to Buy and set a new price target of $93.00 from $65.00 previously
Entered agreement to acquire a portfolio of brands with revenue of $200 million and EBITDA of $95 millionBreathe Right is an iconic and category‑leading brand with strong margins and cash flow generationAcquisition reinforces Prestige's long-term organic growth algorithmTransaction expected to close in Prestige's first half fiscal 2027 TARRYTOWN, N.Y., March 20, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (the "Company" or "Prestige") (NYSE:PBH) today announced that it has entered into a definitive agreement to acquire the Breathe Right® brand and certain other brands from Foundation Consumer Healthcare for $1.045 billion, or approximately $900 million net of anticipated ta
Revenue of $283.4 million in Q3, ahead of outlookDiluted EPS of $0.97 in Q3 and Adjusted Diluted EPS of $1.14, versus prior year Q3 Diluted EPS of $1.22Repurchased approximately 0.8 million shares opportunistically in Q3Successfully closed acquisition of eye care supplier Pillar5 Pharma, Inc. in December, as expectedNarrowing Outlook Range of Fiscal 2026 Revenue and Adjusted Diluted EPS TARRYTOWN, N.Y., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its third quarter and nine months ended December 31, 2025. "We exceeded our third quarter revenue outlook and delivered solid profitability in the quarter, which
TARRYTOWN, N.Y., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (the "Company" or "Prestige") (NYSE:PBH) today announced it will issue its fiscal 2026 third quarter earnings release on Thursday, February 5, 2026 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET. To participate in the live Internet webcast of the conference call, it can be accessed from the Investor Relations page of www.prestigeconsumerhealthcare.com. To participate in the conference call via phone, participants may register for the call here to receive dial-in details and a unique pin. While not required, it is recomme
Better For You Wellness Establishes Strategic Advisory Committee with Industry Leaders and MoreColumbus, Ohio--(Newsfile Corp. - February 10, 2022) - Better For You Wellness, Inc. (OTCQB:BFYW) ("Better For You Wellness" or the "Company"), an Ohio-based company focused on the rapidly-growing $1.5T wellness industry, is pleased to announce the results of the Meeting of the Board of Directors that took place on February 5, 2022, via video conference (the "Board Meeting"). The seven members of the Company's Board of Directors (the "Board") include Ian James, Stephen Letourneau, Montel Williams, Christina Jefferson, Joseph Watson, David Deming, and Dr. Nicola Finley, MD.Establishment of Strategic
SC 13G - Prestige Consumer Healthcare Inc. (0001295947) (Subject)
SC 13G - Prestige Consumer Healthcare Inc. (0001295947) (Subject)
SC 13G/A - Prestige Consumer Healthcare Inc. (0001295947) (Subject)
4 - Prestige Consumer Healthcare Inc. (0001295947) (Issuer)
4 - Prestige Consumer Healthcare Inc. (0001295947) (Issuer)
3 - Prestige Consumer Healthcare Inc. (0001295947) (Issuer)